{"entity":{"id":"fgr","kind":"target","name":"FGR","aka":["FGR proto-oncogene, Src family tyrosine kinase","Tyrosine-protein kinase Fgr","c-fgr","p55c-fgr","SRC2"],"tldr":"FGR (Tyrosine-protein kinase Fgr) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Leukaemia, Myeloproliferative neoplasms, Non-Hodgkin lymphoma and 2 more.","summary":"Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B.\n\nOpen Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.79, animal model 0.49, genetic association 0.00, clinical 0.96).","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:3697","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3697"},{"label":"UniProt P09769","url":"https://www.uniprot.org/uniprotkb/P09769/entry"},{"label":"NCBI Gene 2268","url":"https://www.ncbi.nlm.nih.gov/gene/2268"},{"label":"Ensembl ENSG00000000938","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000000938"}],"tags":["cancer-genes-wave"],"related":["open-targets"],"cancers":["leukaemia","myeloproliferative-neoplasms","non-hodgkin-lymphoma","cml","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.97. Evidence tier \"approved-drug\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"FGR","role":["drug-target"],"evidenceTier":"approved-drug","sources":[{"label":"HGNC HGNC:3697","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3697","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt P09769","url":"https://www.uniprot.org/uniprotkb/P09769/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"Open Targets ENSG00000000938","url":"https://platform.opentargets.org/target/ENSG00000000938/associations","note":"association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: acute lymphoblastic leukaemia 0.55, non-Hodgkin lymphoma 0.55, chronic myelogenous leukaemia, BCR-ABL1 positive 0.58, myeloproliferative neoplasm 0.60, leukaemia 0.61 (GraphQL API, CC0)"}],"distribution":"few-types","specificityNote":"Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA group enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA FGR: RNA group enriched (bone marrow 197 nTPM, lung 83 nTPM, lymphoid tissue 136 nTPM); no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Leukaemia, Myeloid neoplasms, Lymphoma); Open Targets associates it with 2 specific cancer types at or above 0.5 (chronic myeloid leukemia, acute lymphoblastic leukemia). (No rule of scripts/fetch-target-specificity.ts fired.)","specificitySources":[{"label":"Human Protein Atlas FGR tissue","url":"https://www.proteinatlas.org/ENSG00000000938-FGR/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000000938 associations","url":"https://platform.opentargets.org/target/ENSG00000000938/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:3697","ensembl":"ENSG00000000938","uniprot":"P09769","entrez":"2268","firstDescribed":1986,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nishizawa et al, Mol. Cell. Biol, 1986, \"Structure, expression, and chromosomal location of the human c-fgr gene\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/3023853/","biology":"Non-receptor tyrosine-protein kinase that transmits signals from cell surface receptors devoid of kinase activity and contributes to the regulation of immune responses, including neutrophil, monocyte, macrophage and mast cell functions, cytoskeleton remodeling in response to extracellular stimuli, phagocytosis, cell adhesion and migration. Promotes mast cell degranulation, release of inflammatory cytokines and IgE-mediated anaphylaxis. Acts downstream of receptors that bind the Fc region of immunoglobulins, such as MS4A2/FCER1B, FCGR2A and/or FCGR2B. Acts downstream of ITGB1 and ITGB2, and regulates actin cytoskeleton reorganisation, cell spreading and adhesion. Depending on the context, activates or inhibits cellular responses. Functions as a negative regulator of ITGB2 signalling, phagocytosis and SYK activity in monocytes. Location: Cell membrane; Cell projection, ruffle membrane; Cytoplasm, cytosol; Cytoplasm, cytoskeleton (UniProt). Locus 1p35.3 (HGNC).","whereFound":["Leukaemia: Open Targets association 0.61 with leukaemia (MONDO_0005059)","Myeloproliferative neoplasms: Open Targets association 0.60 with myeloproliferative neoplasm (MONDO_0020076)","Non-Hodgkin lymphoma: Open Targets association 0.55 with non-Hodgkin lymphoma (MONDO_0018908)","Chronic myeloid leukaemia: Open Targets association 0.58 with chronic myelogenous leukaemia, BCR-ABL1 positive (MONDO_0011996)","Acute lymphoblastic leukaemia: Open Targets association 0.55 with acute lymphoblastic leukaemia (MONDO_0004967)"],"targetClass":"kinase","prevalence":[]},"route":"/targets/fgr/","neighbours":{"collection":[{"id":"open-targets","kind":"collection","name":"Open Targets Platform","route":"/collections/open-targets/"}],"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"cml","kind":"cancer","name":"Chronic myeloid leukaemia (CML)","route":"/cancers/cml/"},{"id":"leukaemia","kind":"cancer","name":"Leukaemia (all types)","route":"/cancers/leukaemia/"},{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}